# FDA Approves New Breast Cancer Drug Based on VIKTORIA-1 Study Results

> fda · REPORTED · 2026-08-04

The FDA approved a new breast cancer drug based on the VIKTORIA-1 clinical trial results, as reported by Fred Hutchinson Cancer Center in early August 2026. This follows a separate FDA approval earlier in 2026 for vepdegestrant for metastatic ER-positive breast cancer.

About Fred Hutchinson Cancer Center / FDA: The FDA is the U.S. regulatory authority responsible for approving drugs and medical devices; its breast cancer approvals directly impact oncology treatment standards and survivorship care.

- Company: Fred Hutchinson Cancer Center / FDA
- Sector: oncology
- Primary source: https://www.fredhutch.org/en/news/releases/2026/08/tip-sheet-fibromyalgia-risk-fda-approves-breast-cancer-drug-genome-platform-expands.html

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.